New immune cell attack on Hard-to-Treat myeloma begins early testing
NCT ID NCT07399444
First seen Feb 11, 2026 · Last updated May 24, 2026 · Updated 15 times
Summary
This early-phase study tests a new treatment called LVIVO-TaVec400 for people with multiple myeloma that has returned or not responded to standard therapies. About 38 adults will receive the therapy to see if it is safe and to find the best dose. The treatment uses specially modified immune cells to target and attack the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Beijing GoBroad Boren Hospital
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Henan Cancer Hospital
Zhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.